MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2026 International Congress

    Aggregation – Dependent Effects of Wild-Type and Mutant α-Synuclein on Synaptic Membrane Fusion

    M. Sriram, D. Rege, A. Das, R. Nellikka, D. Das (Mumbai, India)

    Objective: 1. What is the endogenous form of ⍺-Synuclein in various cell types?2. How do WT ⍺-Synuclein monomer and aggregates affect presynaptic membrane fusion and the…
  • 2026 International Congress

    Detection of α-synuclein seeds in skin samples from PPMI participants

    Y. Ma, C. Farris, R. Johnson, S. Rosete-Gonzalez, D. Murphy, T. Foroud, L. Concha (San Diego, USA)

    Objective: To evaluate the presence of α-synuclein seeds (syn-seeds) in skin samples from PPMI participants, including prodromal, early and late Parkinson’s disease (PD) using a…
  • 2026 International Congress

    Disparate Subregional Striatal DAT-SPECT Associations with CSF-Synucleinopathy Status and Clinical Severity Across Parkinson’s Disease Continuum

    AD. Droby, BK. Krayem, AM. Mirelman, AT. Thaler (Tel Aviv, Israel)

    Objective: To determine the association between subregional DAT binding ratios (SBRs) for disease risk, PD progression, and whether these associations differ based on SAA status.…
  • 2026 International Congress

    Screening the Neuroprotective Potential of Mushroom Extracts in In Vitro Models of Parkinson’s Disease

    FD. Dustov, SB. Seo (Seoul, Republic of Korea)

    Objective: This study aimed to evaluate the neuroprotective potential of various mushroom extracts across four distinct cellular models of PD. Furthermore, we sought to identify…
  • 2026 International Congress

    Bridging the Genomic Gap: Ancestry-Aware Polygenic Risk and Variant Discovery in African Parkinson’s Disease Cohorts

    B. Adebisi (Osogbo, Nigeria)

    Objective: This study evaluates the shift from Euro-centric data to a diversified landscape. We aim to quantify the performance of European-derived Polygenic Risk Scores (PRS)…
  • 2026 International Congress

    A Novel Genome Editing Strategy for Permanent and Precise Downregulation of α-Synuclein in Parkinson’s Disease

    B. Manohar, R. Wilson (Berkeley, USA)

    Objective: This work aims to develop and evaluate novel nonviral CRISPR-based genome editing strategies to achieve precise and durable transcriptional modulation of SNCA, enabling controlled…
  • 2026 International Congress

    A CSF C Terminal α Synuclein Assay to Differentiate Multiple System Atrophy From Parkinson’s Disease

    P. Kallunki, L. Hansen, J. Wiedemann, L. Rørbæk Olsen, F. Schalk, N. van Demerbel (Valby, Denmark)

    Objective: Differentiating MSA from PD is clinically challenging. We developed CSF assays to measure full length and major C‑terminally truncated α‑synuclein (αSyn) species for potential…
  • 2026 International Congress

    A highly specific skin α-synuclein seed amplification assay for screening of synucleionpathies

    Y. Ma, S. Weber, C. Farris, S. Schnell, J. Kalinkara-Gomez, S. Rosete-Gonzalez, D. Murphy, B. Mollenhauer, L. Concha (San Diego, USA)

    Objective: To evaluate the performance of a skin α-synuclein seed amplification assay (skin_synSAA) as a screening test using samples from movement disorder subjects with uncertain…
  • 2026 International Congress

    Genetic determinants of cognitive performance in Parkinson’s disease: impact of distal regulatory variation at the SNCA locus in the gp2 cohort

    D. Náfate Wences, A. Cervantes Arriaga, M. Rodríguez Violante, MT. Periñán Tocino, GP2. Genetics Program (Mexico City, Mexico)

    Objective: This study evaluates the association between a distal regulatory haplotype at the SNCA locus and cognitive performance, measured by the Montreal Cognitive Assessment (MoCA),…
  • 2026 International Congress

    Multiplexed Serum Biomarkers for Differentiating the Parkinson’s Disease Continuum and Disease Severity

    MS. Kim, IH. Kwak, JK. Yu, H. Ma, K. Choi, J. Kim, H. Hwang, YE. Kim (Hwaseong, Republic of Korea)

    Objective: Reliable blood biomarkers for identifying the Parkinson’s disease (PD) spectrum and reflecting disease severity remain limited. We investigated whether multiple serum biomarkers could differentiate…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley